Zobrazeno 1 - 10
of 927
pro vyhledávání: ''
Autor:
Florentia Dimitriou, Pietro Quaglino, Theodoros Iliakis, P L Ortiz-Romero, Marianna Dalamaga, V. Nikolaou, Martine Bagot, S. Engelina, Stefanie Porkert, E. Papadavid, Vassiliki Pappa, J. Scarisbrick, Constanze Jonak, Emmilia Hodak, C Vico, Emmanuella Guenova, R Guiron, E Kapniari, Antonio Cozzio
Publikováno v:
British Journal of Dermatology. 185:1035-1044
BACKGROUND Brentuximab vedotin (BV) was approved as a therapy for mycosis fungoides (MF) based on the ALCANZA trial. Little real-world data, however, are available. OBJECTIVES To evaluate the efficacy and safety of BV in patients with MF/Sezary Syndr
Autor:
Joseph F. Merola, Alice B. Gottlieb, C E M Griffiths, Pascale Pellet, Luminita Pricop, Weibin Bao, I.B. McInnes, P. Nash, Frank Behrens, Kristian Reich
Publikováno v:
British Journal of Dermatology. 185:1124-1134
BACKGROUND Secukinumab [an interleukin (IL)-17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate-to-severe plaque psoriasis
Autor:
Pascal Joly, A Neale, Dedee F. Murrell, T. Zeeli, P. Stavropoulos, Believe trial investigators, Aikaterini Patsatsi, Rod Sinclair, A-V Roussaki-Schulze, Ioannis D. Bassukas, Frédéric Caux, Johannes S. Kern, P Arora, S. Baum, David Thomas, Victoria P. Werth, S G Gourlay
Publikováno v:
British Journal of Dermatology. 185:745-755
BACKGROUND: Bruton tyrosine kinase (BTK) inhibition targets B-cell and other non-T-cell immune cells implicated in the pathophysiology of pemphigus, an autoimmune disease driven by anti-desmoglein autoantibodies. Rilzabrutinib is a new reversible, co
Publikováno v:
British Journal of Dermatology. 186:726-728
an inadequate response to biologics may reach 30% in psoriasis patients.1,2 In other inflammatory diseases, a positive effect of adding methotrexate (MTX) to adalimumab has been reported.3,4 In this real-world, Canadian multicenter, single-arm, phase
Publikováno v:
British Journal of Dermatology. 186:189-191
Infantile haemangiomas (IH) affect up to 4% of infants and are the most common tumour of infancy. Although self-limiting, some lesions can lead to visual impairment, airway obstruction, ulceration or cosmetic disfigurement and require intervention. O
Publikováno v:
BRITISH JOURNAL OF DERMATOLOGY, 186(4), 721-723. Wiley
Pemphigoid is a heterogeneous group of rare and chronic autoimmune subepidermal bullous diseases, characterized by circulating autoantibodies against structural proteins in the hemidesmosomes. Long-term therapy with systemic oral prednisone and immun
Autor:
Z. Kaymakcalan, Yonghao Cao, D M Conlon, L Sidur, F Hong, Carolyn A. Cuff, Y Fang, Melanie C. Ruzek, Kristine M. Smith
Publikováno v:
British Journal of Dermatology. 185:804-814
Background Adalimumab provides significant efficacy for patients with hidradenitis suppurativa (HS), which was demonstrated by at least 50% of patients achieving a clinical response by week 12 that was maintained through to week 168 in the PIONEER tr
Autor:
E Hwang, M.M. Tomayko
Publikováno v:
The British Journal of Dermatology
Autoimmune blistering diseases (AIBD) are often treated with immunosuppressive medications, including rituximab, yet the implications of these approaches during the COVID‐19 pandemic are not fully understood. COVID‐19 outcome studies in AIBD pati
Publikováno v:
British Journal of Dermatology. 185:851-853
Autor:
Aaron K. Aragaki, Steven R. Feldman, Delphine J. Lee, C T Yang, Aladdin H. Shadyab, J Noguti, JE Manson, Robert B. Wallace, Alfred A. Chan, Rowan T. Chlebowski
Publikováno v:
British Journal of Dermatology. 185:669-671
Estrogen level fluctuations have been linked to psoriasis (1); however, the association between menopausal hormone therapy and risk of psoriasis is largely unexplored. We analyzed data from the Women's Health Initiative's (WHI) randomized controlled